Objective:
To discuss the clinical experiences with XIPERE and microneedle technology for treating uveitis.
Approach:
- Interview with Dr. Chin Yee: Dr. Chin Yee shares insights on the use of XIPERE and microneedle technology for delivering treatment directly into the suprachoroidal space.
Key Findings:
- XIPERE is an FDA-approved corticosteroid that can be delivered directly into the suprachoroidal space using microneedle technology.
- This delivery method allows for better targeting of inflammation in the macula and potentially reduces side effects associated with traditional steroid treatments.
Interpretation:
The suprachoroidal space is an important target for treatment as it allows for direct access to the source of inflammation in uveitis.
Limitations:
- There may be a learning curve associated with the new microneedle technology.
- Funding for research in this area can be challenging.
Conclusion:
Collaboration between engineering and medicine is crucial for advancing ophthalmic innovations and improving patient outcomes.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
